Yeah, the MM will keep this pinned under $5 and steal from the retail investor once again. It has been painful watching this fall from the 10's after the SNY partnership, all the way down to the 2014 low's again. I wonder what Al and the rest of the board knows that we don't. There has to be something going on, or it wouldn't be this quite for this long.
The carry forward loss on MNKD alone justifies a 2 billion dollar market cap and that's where we sit today. By the end of May I bet it's back in the 7's again.
I'm not sure anyone wants to short this stock where it is and that's why you're seeing it consolidate at the 4.90-5.10 levels. 37% of the float is short, so yeah it is becoming very difficult to borrow shares but the simple fact that any positive headlines that come out now will cause a pretty decent squeeze. I think adding or getting in at this level is very wise based on some historical support levels that were built in last year. I'm guessing you'll hear some positive news any day now.
What control does Al have now besides absolutely tanking the stock if he sells? SNY holds all the cards and so far they have mutilated the launch.
MNKD will never make it. They gave away 65% of the profits for one of the worst marketing campaigns ever for a drug that was suppose to take on a blockbuster status. I don't know how MNKD's balance sheet is going to survive with the slow start, terrible split, and a partner that has put in a pitiful effort so far. They are going to have to split again over the next couple of months to have enough cash to keep the company running.
This move in share price is driven by valuation and current estimates that's all. People blaming shorts are not seeing the bigger picture. This shouldn't be a five dollar stock at the moment based on its fundamentals. The company has done everything ok up to this point, but the deal with SNY is lackluster so far since they haven't done much to validate 65% of the profits. The marketing and salesforce resources that they have put into action is for afreeza is pitiful. Makes me still believe that SNY long term goal is to mute Afreeza, promote their diabetes line, and possibly buy the rights to Afreeza in the future at a massive bargain once it implodes.
Shorts won't cover until the company shows a profit, just like the TSLA short squeeze a few years back.
If you wanna make money in MNKD you need to know how to trade the range. I'm not sure why they are delaying the EU approval and why SNY is being so lame with this soft launch. Until you see EU approval and SNY launching major TV ads this thing with continue to be manipulated up and down.
I'm ready to load up when it gets there. There aren't any near term events to help stabilize this down trend. I have to believe that with the low volume and how easy it is to manipulate the PPS that we will see another breach of the 5 dollar level in the coming months.
He's right, the stock is still over valued. I'm not buying until we see low 4's again. It's not like Afreeza is selling off the shelves right now anyway with this slow, controlled launch. Until word spreads and more doctors and patients ask for it, we will see modest sales numbers. I blame SNY, they haven't treated this drug like a real player in the diabetes market.
I've seen this same trading action for the past 2 years. It will bounce then next thing you know it's in the 4's. I'm not getting tricked into falling for the small pop.
Nobody knows how this is going to play out. It's all speculation, that's what investing in biotech is all about. If you're taking investment advice from doctors or lawyers, which in my experience are the worst investors out there because of their over confidence, then you're playing with fire. I think you'll see this stock fluctuate in this 5-7 dollar range for a long time. The demand has been modest so far and revenues are going to be slow for a while so you really need patience to see how this thing plays out over the next 5 years to really benefit from a short squeeze. People that believe that a squeeze is going to happen near term aren't being realistic.
7.10 wow thanks a lot MNKD. After waiting through trial results, NDA, Adcom, FDA approval, and partnership I'm at the same spot where I started. This stock is helpless to the constant short raids and bash articles because management has their heads up you know where. They do nothing to combat it and where is this aggressive marketing campaign that we were suppose to see. This soft launch is awful. Paid 65% of revenues for what??? I want to know what's going on with the marketing strategy. As investors we deserve to know what the business plan is and they just shut there mouths about everything.
It baffles me that doctors and researchers in the field of diabetes still don't know about Afreeza and it's benefits. Why wouldn't you be studying new drugs and delivery methods to help your patients? Seems wrong that they don't take the time to look into all the drugs in the diabetes pipeline. Wouldn't you expect that from your doctor if you have diabetes?
I was expecting more from the product launch myself. They've had plenty of time to put together an aggressive plan to get Afreeza in the media, but I'm not seeing much thus far. With this kind of meager activity, you could be right. I was expecting the low 6's yesterday after the news, it could be a few days away still.
Opc is spot on. You can't say anything negative on this board or you're automatically a short. That's why pumpers and overly optimistic investors always lose money in the end. I've been long for about 2 years now and have gone through a ton of risk to see modest gains. I did dump a large portion of my holdings after the SNY deal knowing that we'd have to wait months for a product launch. Well here it is and the share price again is tanking as usual on the news.